NIRVF (Nirvana Life Sciences) OCF Margin %: 0.00% (As of Jan. 2026)


What is Nirvana Life Sciences OCF Margin %?

Nirvana Life Sciences NIRVF OCF Margin % is 0.00% as of Jan. 2026. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Nirvana Life Sciences ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Nirvana Life Sciences's Cash Flow from Operations for the three months ended in Jan. 2026 was $-0.00 Mil. Nirvana Life Sciences's Revenue for the three months ended in Jan. 2026 was $0.00 Mil. Therefore, Nirvana Life Sciences's OCF Margin % for the quarter that ended in Jan. 2026 was 0.00%.

As of today, Nirvana Life Sciences's current OCF Yield % is -77.13%.

The historical rank and industry rank for Nirvana Life Sciences's OCF Margin % or its related term are showing as below:


NIRVF's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Nirvana Life Sciences OCF Margin % Related Terms

Nirvana Life Sciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences OCF Margin % Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Nirvana Life Sciences's OCF Margin for the fiscal year that ended in Apr. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Apr. 2025 )/Revenue (A: Apr. 2025 )
=-0.049/0
= %

Nirvana Life Sciences's OCF Margin for the quarter that ended in Jan. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=-0.003/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Nirvana Life Sciences (NIRVF) has a OCF Margin % of 0.00% as of Jan. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nirvana Life Sciences and its competitors. According to the industry distribution chart, Nirvana Life Sciences ranks #999999 out of 954 companies in the Biotechnology industry.
Is Nirvana Life Sciences' OCF Margin % too high?
Nirvana Life Sciences' current OCF Margin % is 0.00%. Based on the distribution chart, Nirvana Life Sciences ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nirvana Life Sciences' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nirvana Life Sciences ranks #999999 out of 954 companies for OCF Margin %. This places Nirvana Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nirvana Life Sciences and its competitors. Nirvana Life Sciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current OCF Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.